These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16830064)

  • 21. [The clinical efficacy of Bladder Chek NMP22 in urothelial cancer].
    Yokoyama T; Sekigawa R; Hayashi T; Horita S; Kanamuro T; Nonami Y; Sawada T; Nishikawa T; Kobayashi M; Yamaguchi Y; Ishida H; Goya N; Nakazawa H; Toma H
    Rinsho Byori; 2004 Mar; 52(3):199-203. PubMed ID: 15137316
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
    Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
    Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
    Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
    APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer.
    Yu J; Zhu T; Wang Z; Zhang H; Qian Z; Xu H; Gao B; Wang W; Gu L; Meng J; Wang J; Feng X; Li Y; Yao X; Zhu J
    Clin Cancer Res; 2007 Dec; 13(24):7296-304. PubMed ID: 18094410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs.
    Eissa S; Kassim SK; Labib RA; El-Khouly IM; Ghaffer TM; Sadek M; Razek OA; El-Ahmady O
    Cancer; 2005 Apr; 103(7):1356-62. PubMed ID: 15717321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of the novel marker BLCA-1 for the detection of bladder cancer.
    Myers-Irvin JM; Landsittel D; Getzenberg RH
    J Urol; 2005 Jul; 174(1):64-8. PubMed ID: 15947579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder.
    Staack A; Badendieck S; Schnorr D; Loening SA; Jung K
    BMC Urol; 2006 Aug; 6():19. PubMed ID: 16901349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment.
    Szarvas T; Kovalszky I; Bedi K; Szendroi A; Majoros A; Riesz P; Füle T; László V; Kiss A; Romics I
    Oncol Rep; 2007 Aug; 18(2):405-9. PubMed ID: 17611663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular markers in bladder cancer: a critical appraisal.
    Konety BR
    Urol Oncol; 2006; 24(4):326-37. PubMed ID: 16818187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
    Jamshidian H; Kor K; Djalali M
    Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of tissue-polypeptide specific antigen (TPS) in bladder cancer.
    Menendez V; Galan JA; Fernandez-Suarez A; Lopez S; Alcover J; Calpena R; Filella X
    Anticancer Res; 2002; 22(6B):3713-6. PubMed ID: 12552981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Telomerase and other novel approaches to bladder cancer detection.
    Bennett A
    Clin Lab Sci; 2008; 21(3):185-90; quiz 191-2, following 192. PubMed ID: 18678141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum antibodies against prostasomal clusterin in prostate cancer patients.
    Ronquist KG; Carlsson L; Ronquist G; Semjonow A; Wülfing C; Larsson A
    Scand J Clin Lab Invest; 2008; 68(3):219-27. PubMed ID: 17926197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.
    Bian W; Xu Z
    Int J Urol; 2007 Feb; 14(2):108-11. PubMed ID: 17302565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine.
    Eissa S; Ali-Labib R; Swellam M; Bassiony M; Tash F; El-Zayat TM
    Eur Urol; 2007 Nov; 52(5):1388-96. PubMed ID: 17466450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of seven screening methods in the diagnosis of bladder cancer.
    Sun Y; He DL; Ma Q; Wan XY; Zhu GD; Li L; Luo Y; He H; Yang L
    Chin Med J (Engl); 2006 Nov; 119(21):1763-71. PubMed ID: 17097029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary nucleosides based potential biomarker selection by support vector machine for bladder cancer recognition.
    Mao Y; Zhao X; Wang S; Cheng Y
    Anal Chim Acta; 2007 Aug; 598(1):34-40. PubMed ID: 17693304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Telomerase activity: a molecular marker for early diagnosis of bladder tumor].
    Calistri D; Sanchini A; Amadori D; Silvestrini R
    Recenti Prog Med; 2007 Feb; 98(2):74-8. PubMed ID: 17439065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methylational urinalysis: a prospective study of bladder cancer patients and age stratified benign controls.
    Yates DR; Rehman I; Meuth M; Cross SS; Hamdy FC; Catto JW
    Oncogene; 2006 Mar; 25(13):1984-8. PubMed ID: 16288222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis.
    Lotan Y; Svatek RS; Sagalowsky AI
    Cancer; 2006 Sep; 107(5):982-90. PubMed ID: 16862567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.